Business
CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference
Data further support choice of patient population and dosing regimen in CervoMed's planned Phase 3 trial in dementia with Lewy bodies (DLB) DLB is the second
About this update from Cervomed Inc.
[{"type":"text","content":"Data further support choice of patient population and dosing regimen in CervoMed's planned Phase 3 trial in dementia with Lewy bodies (DLB) DLB is the second most common progressive dementia, affecting millions worldwide, and has no approved treatments in the United States or European Union BOSTON, March 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that neflamapimod, an oral, small molecule, drug candidate targeting critical disease processes underlying degenerative disorders of the brain, will be featured in an oral presentation and a scientific symposium at AD/PD 2026 in Copenhagen, Denmark, taking place March 17-21, 2026. In the Phase 2b RewinD-LB trial, neflamapimod demonstrated a statistically significant and clinically meaningful slowing of clinical progression in patients with dementia with Lewy bodies (DLB) who did not have Alzheimer’s disease (AD) co-pathology during the trial’s extension phase. The secondary analyses of data from the trial to be presented at AD/PD 2026 will include new outcomes by pre-specified plasma pTau181 levels that further support the cutoff to be utilized in the Company’s planned Phase 3 trial in DLB patients to enrich for those without AD co-pathology. The primary and secondary analyses of the study will be presented by Dr. John-Paul Taylor, MBBS(hons) MRCPsych PhD, Professor of Translational Dementia Research at Newcastle University, United Kingdom (UK) and Chief Investigator of the RewinD-LB trial for the UK. In addition, CervoMed will be sponsoring a scientific symposium that focuses on how advances in DLB research are leading to new, mechanism-based drug development strategies. The symposium will include presentations from Dr. Niels Prins, MD, PhD, Brain Research Center, Amsterdam, and Dr. John Alam, CEO, CervoMed, and will highlight scientific, mechanistic, pharmacologic, and clinical data supporting the inhibition of p38 map kinase as a potential promising treatment for DLB. This will include results of new PK/PD analyses (i.e., blood drug concentration relationships) from the RewinD-LB trial that increase the understanding of neflamapimod dose-response in DLB and support the Company’s proposed dosing regimen for its planned Phase 3 trial. O...